A5049549108- Monoclonal and Polyclonal Antibodies Research
- Protein Structure and Dynamics
- Protein purification and stability
- Chemical Synthesis and Analysis
- HER2/EGFR in Cancer Research
- Bacteriophages and microbial interactions
- Nerve injury and regeneration
- T-cell and B-cell Immunology
- Parkinson's Disease Mechanisms and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Viral Infectious Diseases and Gene Expression in Insects
- Glycosylation and Glycoproteins Research
- Bacterial Genetics and Biotechnology
- RNA and protein synthesis mechanisms
- CAR-T cell therapy research
- Toxin Mechanisms and Immunotoxins
- Cancer Immunotherapy and Biomarkers
- Machine Learning in Bioinformatics
- Sulfur-Based Synthesis Techniques
- Biosimilars and Bioanalytical Methods
- RNA regulation and disease
- Fluorine in Organic Chemistry
- Click Chemistry and Applications
- Neuroblastoma Research and Treatments
- Zebrafish Biomedical Research Applications
Boehringer Ingelheim (United States)
2016-2024
Nanotherapeutics (United States)
2022
Pearl River Community College
2003-2008
Computational Physics (United States)
2004
Upregulation of inhibitory receptors, such as lymphocyte activation gene-3 (LAG-3), may limit the antitumor activity therapeutic antibodies targeting programmed cell death protein-1 (PD-1) pathway. We describe binding properties ezabenlimab, an anti-human PD-1 antibody, and BI 754111, LAG-3 assess their alone in combination. Ezabenlimab bound with high affinity to human (KD = 6 nM) blocked interaction PD-L1 PD-L2. dose-dependently increased interferon-γ secretion T cells expressing...
Structural features of two weak inhibitors the ZipA-FtsZ protein-protein interaction which were found to bind overlapping but different areas key binding site combined in one new series carboxybiphenyl-indoles with improved inhibitory activity.
Antibodies with pH-dependent binding to both target antigens and neonatal Fc receptor (FcRn) provide an alternative tool conventional neutralizing antibodies, particularly for therapies where reduction in antigen level is challenging due high burden. However, the requirements optimal kinetic framework extent of pH dependence these antibodies maximize clearance from circulation are not well understood. We have identified a series naturally-occurring affinity properties. By vivo studies...
Therapeutic agents antagonizing B-cell-activating factor/B-lymphocyte stimulator (BAFF/BLyS) are currently in clinical development for autoimmune diseases; belimumab is the first Food and Drug Administration-approved drug more than 50 years treatment of lupus. As a member tumor necrosis factor superfamily, BAFF promotes B-cell survival homeostasis overexpressed patients with systemic lupus erythematosus other diseases. exists three recognized forms: membrane-bound two secreted, soluble forms...
Purpose: Semaphorin 3A (Sema3A) is an axonal guidance molecule that inhibits angiogenesis by vasorepulsion and blocks revascularization in the ischemic retina. BI-X intravitreal anti-Sema3A agent under clinical investigation patients with proliferative diabetic retinopathy (PDR) macular ischemia (DMI). Methods: Surface plasmon resonance was used to determine binding affinity of human murine Sema3A. In vitro, retinal microvascular endothelial cells (HRMECs) were assess effects on cell...
Due to the refractiveness of tumor tissues adeno-associated virus (AAV) transduction, AAV vectors are poorly explored for cancer therapy delivery. Here, we aimed engineer AAVs target tumors by enabling specific engagement fibroblast activation protein (FAP). FAP is a cell surface receptor distinctly upregulated in reactive stroma, but rarely expressed healthy tissues. Thus, targeting presents an opportunity selectively transduce To achieve this, modified capsid AAV2 with αFAP nanobody...
An in-house antibody generation campaign identified a diverse, high affinity set of anti-interleukin-11 (IL-11) monoclonal antibodies (mAbs) to enable successful development novel, custom ultra-sensitive target engagement assays for detection "free" (unbound the dosed anti-IL-11 therapeutic mAb) and "total" (free mAb-IL-11 complexed form) IL-11 in preclinical species human. Antibody hits from distinct epitope communities were screened on various platforms, including enzyme-linked...
Prion-like transmission of pathology in α-synucleinopathies like Parkinson's disease or multiple system atrophy is increasingly recognized as one potential mechanism to address progression. Active and passive immunotherapies targeting insoluble, aggregated α-synuclein are already being actively explored the clinic with mixed outcomes so far. Here, we report identification 306C7B3, a highly selective, aggregate-specific antibody picomolar affinity devoid binding monomeric, physiologic...
The fully automated microfluidics-based Gyrolab is a popular instrument for the bioanalysis of protein therapeutics; requiring minimal sample and reagent volumes. Gyros offers affinity software determining binding in solution using high-throughput method miniaturized reactions.Using this software, multiple CTGF-targeting reagents were characterized on after <100% target coverage was seen cynomolgus pharmacokinetic/PD study dosed with anti-CTGF antibodies. results uncovered magnitude...
Discovery and optimization of a biotherapeutic monoclonal antibody requires careful balance target engagement physicochemical developability properties. To take full advantage the sequence diversity provided by different discovery platforms, rapid reliable process for humanization antibodies from nonhuman sources is required. Canonically, maximizing homology human variable region (V-region) to original germline was believed result in preservation binding, often without much consideration...
Abstract Prion-like transmission of pathology in α-synucleinopathies like Parkinson’s disease or multiple system atrophy is increasingly recognized as one potential mechanism to address progression. Active and passive immunotherapies targeting insoluble, aggregated α-synuclein are already being actively explored the clinic with mixed outcomes so far. Here, we report identification 306C7B3, a highly selective, aggregate-specific antibody picomolar affinity devoid binding monomeric,...